LJPC: - 33.25, $761.69M, -1.11 (-3.23%)

Sector: Healthcare - Industry: Biotechnology

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It engages in developing LJPC-501, a formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome; and LJPC-401, a formulation of hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. The company is also developing LJPC-30Sa and LJPC-30Sb, which are the gentamicin derivatives for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.Key Statistics

Past LJPC reports

Earning Date	Time	Title	EPS-e	EPS-a	Close	Prev Close	Open	Day Low	Day High	Gap %	CFO %	Change %	Volume
2017-02-23	AMC		-1.2		19.87	18.22	17.6	17.26	20.38	-3.40%▲	12.90%	9.06%	656.84K
2016-08-08	AMC		-0.99		18.12	18.25	18.32	17.63	19.07	0.38%	-1.09%	-0.71%	123.12K
2016-08-05	AMC		-0.99
2016-05-06	AMC		-0.74
2016-04-29	AMC		-0.74
2016-04-28	AMC		-0.74		18.51	18.7	18.69	17.7	18.95	-0.05%	-0.96%	-1.02%	134.95K
2016-04-27	AMC		-0.74		18.7	19.37	19.14	18.54	19.69	-1.19%	-2.30%	-3.46%	106.80K
2015-11-06			-0.71
2015-08-07			-0.61
2014-11-14		La Jolla Pharma	-0.42	-0.37	11.04	11.06	11	10.98	11.44	-0.54%	0.36%	-0.18%	127.60K
2014-08-15		La Jolla Pharma	-0.74	-0.63	10.29	9.83	9.57	9.57	10.48	-2.64%	7.52%	4.68%	207.90K
2014-05-12		La Jolla Pharma	-0.91	-0.93	8.76	8.83	8.92	8.67	9.23	1.02%	-1.79%	-0.79%	73.40K
2014-04-07		La Jolla Pharma	-0.2	-72.74	11.52	10.27	10.2	9.82	12.08	-0.68%	12.94%	12.17%	519.60K